Compare DVAX & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVAX | CXM |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2004 | 2021 |
| Metric | DVAX | CXM |
|---|---|---|
| Price | $15.50 | $6.01 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $26.50 | $9.89 |
| AVG Volume (30 Days) | ★ 2.6M | 2.1M |
| Earning Date | 02-20-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 180.38 |
| EPS | N/A | ★ 0.42 |
| Revenue | $330,514,000.00 | ★ $839,147,000.00 |
| Revenue This Year | $24.63 | $8.25 |
| Revenue Next Year | $15.85 | $3.44 |
| P/E Ratio | ★ N/A | $14.14 |
| Revenue Growth | ★ 26.73 | 6.48 |
| 52 Week Low | $9.20 | $5.80 |
| 52 Week High | $15.73 | $9.69 |
| Indicator | DVAX | CXM |
|---|---|---|
| Relative Strength Index (RSI) | 76.15 | 25.09 |
| Support Level | $15.46 | $5.80 |
| Resistance Level | $15.59 | $6.16 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 15.22 | 15.70 |
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.